MANAGEMENT & BOARD OF DIRECTORS BIOBBIOS

Transcription

1 MANAGEMENT & BOARD OF DIRECTORS BIOBBIOS CHRISTOPHER IANELLI, MD, PHD Chief Executive Officer & Board Member Chris conceptualized and founded ispecimen to address the growing need for human biospecimens by the life science research communities. He is responsible for the company s growth and performance since its inception and actively oversees the corporate direction and many of the new strategic partnerships. Chris has successfully managed ispecimen technology development and its expansion into additional partner supply sites. Prior to launching ispecimen, Chris served as Managing Director at Leerink Swann, a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. Chris was also a co-founder of Health Insight Technologies (now Humedica), a novel healthcare informatics company. Prior to this, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors (BMSA), a healthcare investment research firm acquired by Leerink Swann. He received both his PhD in Immunology and his MD from Tufts University and completed his residency training, including one year as Chief Resident, in Pathology at Brigham & Women s Hospital and Harvard Medical School. DAVID WAGES, MD, PHD Chief Medical Officer David is responsible for ensuring that ispecimen meets the medical research needs of customers. This includes ensuring that specimens are of the highest quality and that ispecimen technology will continue to meet the increasingly sophisticated needs of the academic, pharmaceutical, and government research communities. Prior to joining ispecimen, David served as Senior Medical Director at Quintiles, the world s largest clinical research organization, where he supported both large pharmaceutical companies as well as smaller biotech organizations in a wide variety of clinical oncology programs. David has worked in both start-up biotechs and large pharma. David began his career working on the clinical development of novel drug-device combinations for blood decontamination at Cerus Corporation. He then worked on clinical trials at Wyeth that led to the development of Xyntha, a drug used to treat hemophilia. After a brief stint assisting institutional investors on healthcare technology opportunities at Leerink- Swann s Medacorp, David then moved on to ARIAD Pharmaceuticals where he turned to cancer research, working on ARIAD s mtor inhibitor for solid tumors as well as initiating ARIAD s phase I trial for chronic myeloid leukemia drug, Iclusig. David next joined EMD Serono where he worked on phase I-III trials of immune-agents for oncology. David holds an MD and PhD from the University of Virginia School of Medicine where he focused on the basic science of oncology. He then completed a residency at the University of California, San Francisco and a fellowship in hematopathology at Boston s Beth Israel hospital. DOUG WILLIAMS Chief Technology Officer Doug is responsible for leading the team that builds ispecimen s innovative, state-of-the-art cloud-based platform implemented at hospital and lab sites nationwide. By aggregating labs, biorepositories, and other organizations with access to human biospecimens into one pool from which to pull, ispecimen s technology consolidates, sorts, and procures a wealth of specimens and data for the myriad organizations that need them, serving as a one-stop source for researchers at biotech, pharma, and academic institutions.

2 Doug has over 25 years of experience leading product development teams building market-leading web and mobile products for consumers and industry. Most recently, as Vice President of Engineering at FitnessKeeper, he realized his dream of developing software to help people stay fit and lead more active lives. With over 40 million users, Fitness- Keeper has won Time s Top 50 Apps twice. Prior to FitnessKeeper, Doug led the technology and product teams at numerous successful startups, including Zipcar, the world s leading car-sharing network, and Family Education, the largest K-12 educational community. Doug has his Bachelor of Science degree in Electrical Engineering and Computer Science from Princeton University and his MBA from Harvard. He also holds three patents. Doug is passionate about fitness and has completed the Boston Marathon for Dana-Farber and the 150-mile Pan Mass Challenge and BikeMS rides to raise money for cancer and Multiple Sclerosis research. BRUCE CRANNA Chief Financial Officer and Vice President of Corporate Development As CFO, Bruce overseas the financial direction of ispecimen and serves as an advisor regarding corporate financial planning. He is also responsible for driving strategic business development initiatives by establishing and maintaining high level relationships with global diagnostic and therapeutic companies. Bruce joins ispecimen after more than 12 years as a Senior Equity Analyst covering diagnostic and lab service companies for ABN AMRO, Leerink Swann, and Jefferies & Company. He was named as a Wall Street Journal All-Star Analyst multiple times, and earned a #1 ranking in both the 2008 Financial Times World s Best Analysts and Forbes Best Brokerage Analysts surveys. Over the course of his Wall Street career, Bruce published thousands of pages of research on diagnostic technologies and life science companies, and was involved in more than $1 billion of capital raises and M&A transactions. Previously, he was a Senior Healthcare Consultant at the former Coopers & Lybrand and served as a Senior Analyst at Blue Cross and Blue Shield of Massachusetts. Mr. Cranna received an MBA from Northeastern University, cum laude and a BA from the University of Massachusetts, Amherst cum laude. JILL MULLAN Chief Operating Officer & Board Member Jill is responsible for ensuring operational excellence throughout the company. In this position, she oversees ispecimen s supply partner programs and operations, human resources, marketing, corporate communications, and corporate strategy. She is also responsible for ensuring regulatory compliance, privacy and security across the company s operations. Jill has over 25 years of experience in operational management, strategy, and marketing. Before joining ispecimen, Jill ran a consulting business to help companies develop business and product strategies, raise funds, create brands, and launch new products. Prior to that, Jill was on the founding team and Director of Marketing at Storigen Systems, where she built and ran the company s marketing organization, developed the company s brand identity, and launched several successful products. She was also the Director of Product Marketing and Management at Avid Technology, managing the P&L for Avid s $400M editing product line. Jill graduated with distinction from Cornell University with a BS in electrical engineering and received her MBA from Stanford University.

3 ERIC LANGLOIS Vice President of Sales & Business Development Eric is responsible for driving and managing all aspects of company sales and business development. In this position, he applies his strategic vision as well as day-to-day execution on initiatives related to revenue generation and account management. He also plays a key role in analyzing and developing the supply partner network in order to meet the demands of ispecimen s rapidly expanding customer base. Eric has amassed nearly 20 years of experience in the arena of preclinical sample collections and biobanking for translational research. Before joining ispecimen, Eric was Head of North American Sales for the ReproCell Group. He helped build and manage a sales team driven by the demands of integrating four portfolio companies with products and services in Cellular Reprogramming, Stem Cells, 3D cell culture, and biospecimens. Prior to that, he held rapidly increasing positions from Regional Sales Manager to VP of Sales with Genomics Collaborative, SeraCare Life Sciences, SeqWright, and BioServe. For over a decade Eric and his teams have proven quite successful at driving revenue using a consultative, customer-centric approach. Eric holds a BS in Biotechnology/Biochemistry from Worcester Polytechnic Institute. DAWN MICHELLE Senior Director of Supply Operations Dawn and her team manage all aspects of supply operations at ispecimen, from understanding researcher requirements through fulfillment, working closely with ispecimen s network of partner laboratories and biorepositories. Dawn and her team are responsible for implementing ispecimen s technology at partner sites, ensuring each supplier s data is properly harmonized to industry standards, and optimizing ispecimen-related operations to run efficiently at each site. Dawn has over 25 years of clinical laboratory management experience with an emphasis in regulatory oversight. Dawn was formerly the Director of Operations for the Partners Biorepository for Medical Discovery, where she was responsible for providing the Partners research community with a repository and related services to support clinical, translational, and basic science research programs. Prior to that she managed the implementation of a new laboratory information system for the blood transfusion service at Brigham and Women s Hospital. She received a BS in Clinical Laboratory Science from Georgia State University earning MT(ASCP) certification. Later, she earned a Specialist in Blood Banking (SBB) certification. She holds an MS in Computer Information Systems from Boston University. BRAD CALLOW Director of Finance & Human Resources Brad is responsible for driving finance and recruiting across ispecimen s business. In this role, he focuses on managing the company s assets and financial planning as well as building up the human capital to meet performance goals. Brad is truly the company s culture czar. Prior to ispecimen, Brad was a Principal at Boston Millennia Partners, an early stage healthcare venture capital firm where he managed the deal flow team and assisted the firm in bringing multiple companies to exit. Prior to that, he

4 worked in project management at Millennium Pharmaceuticals (acquired by Takeda) on multiple oncology drugs. Brad received his MBA from the Tuck School of Business at Dartmouth and received his BS from Tufts University. KIRAN GANDA Director of Marketing Kiran is responsible for driving all aspects of company marketing and corporate communications. She provides strategic direction as well as day-to-day execution on initiatives spanning branding, promotions, public relations, thought leadership, events, and interactive marketing. Kiran joined ispecimen with dedicated experience in healthcare technology and services marketing, having most recently served as Director of Marketing & Communications at Advanced Practice Strategies (APS). Prior to APS, Kiran held successive marketing and communications roles at Health Dialog, ultimately serving as the company s Director of Communications. Kiran began her career in the health technology practice at global public relations firm, Brodeur Partners. She holds a BS from Tufts University summa cum laude and an MBA from Boston College. LUIS NICOLAOU Director of Product Management Luis is responsible for driving all aspects of product management. He works with customers, partners, and the ispecimen team to define and build the product offerings that deliver measurable benefits to all. Luis has over 15 years of experience in the software industry spanning software development, professional services, and product management. He has held positions at start-ups for the majority of his career, contributing to their successful exits along the way. Luis earned his BS in Mathematics and Computer Science from Tufts University. ANDREW ROSS Board Member Andrew is a lifelong entrepreneur and private investor with a focus on early stage investments in biotechnology, collaborative consumption, and cause-focused enterprise. GEORGE BUD SCHOLL Board Member Bud has been an entrepreneur for most of his professional life. He has primarily focused on purchasing and working out distressed assets across a variety of industries and asset types. He has developed and invested in financial, real estate, service and technology companies. Bud currently serves as the Chief Strategy Officer of OneBlood, which was formed in 2012 as a result of a merger he organized, when he was Chairman and CEO of the Community Blood Centers of Florida, one of the three largest blood centers in the southeastern United States. Bud also currently serves as the mayor of the City of Sunny Isles Beach, Florida, where he was elected in 2014 after serving as City Commissioner for seven years. Bud

5 is a graduate of the University of Florida and holds an engineering degree in computer science. In his leisure time, Bud enjoys skiing, boating, restoring old games, and playing guitar. ispecimen Inc. 450 Bedford Street, Lexington, MA ispecimen.com 2016 ispecimen Inc. ispecimen and the ispecimen logo are registered trademarks of ispecimen Inc. All other trademarks are property of their respective owners.